![conference banner](/images/conference-banner.jpeg)
Abstract
Thrombosis is the condition where an imbalance in the homeostatic mechanism results in unwanted intravascular thrombus formation. Imbalances in this highly regulated process of coagulation and anticoagulation can lead to a variety of pathophysiological conditions leading to stroke, pulmonary heart attack and other serious conditions. In the western world, thromboembolic diseases are the leading cause of morbidity and mortality. Remarkable progress has occurred over the last decade in the development of antithrombotic drugs, which can be classified into 3 major categories – Anticoagulants, Antiplatelets and thrombolytics. Increased understanding of the pathobiology of thrombotic and vascular disorders has helped researchers to target novel pathways involving the coagulation, thrombolytic, fibrinolytic and integrin systems. Traditionally aspirin and unfractionated heparin was used for myocardial infarction. Newer antiplatelet agents such as, clopidogrel, GP IIb/IIIa inhibitors, low molecular weight heparin, direct thrombin inhibitors and several improved thrombolytic agents have been introduced for clinical use. This review will discuss different important drugs, which have been launched in recent years and also some new targets pursued by different companies.
Keywords: deep vein thrombosis, Anticoagulants, Warfarin, Fondaparinux Sodium, Antiplatelet therapies, Direct Factor Xa Inhibitors
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Advances in Antithrombotic Agents
Volume: 5 Issue: 3
Author(s): Ranjan Chakrabarti and Saibal Kumar Das
Affiliation:
Keywords: deep vein thrombosis, Anticoagulants, Warfarin, Fondaparinux Sodium, Antiplatelet therapies, Direct Factor Xa Inhibitors
Abstract: Thrombosis is the condition where an imbalance in the homeostatic mechanism results in unwanted intravascular thrombus formation. Imbalances in this highly regulated process of coagulation and anticoagulation can lead to a variety of pathophysiological conditions leading to stroke, pulmonary heart attack and other serious conditions. In the western world, thromboembolic diseases are the leading cause of morbidity and mortality. Remarkable progress has occurred over the last decade in the development of antithrombotic drugs, which can be classified into 3 major categories – Anticoagulants, Antiplatelets and thrombolytics. Increased understanding of the pathobiology of thrombotic and vascular disorders has helped researchers to target novel pathways involving the coagulation, thrombolytic, fibrinolytic and integrin systems. Traditionally aspirin and unfractionated heparin was used for myocardial infarction. Newer antiplatelet agents such as, clopidogrel, GP IIb/IIIa inhibitors, low molecular weight heparin, direct thrombin inhibitors and several improved thrombolytic agents have been introduced for clinical use. This review will discuss different important drugs, which have been launched in recent years and also some new targets pursued by different companies.
Export Options
About this article
Cite this article as:
Ranjan Chakrabarti and Saibal Kumar Das , Advances in Antithrombotic Agents, Cardiovascular & Hematological Agents in Medicinal Chemistry 2007; 5 (3) . https://dx.doi.org/10.2174/187152507781058717
DOI https://dx.doi.org/10.2174/187152507781058717 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of Improvement of Left Ventricular Function by Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Infusion in Very Old Patients with Coronary Chronic Total Occlusion
Current Pharmaceutical Design Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews Statins in the Treatment of Acute Ischemic Stroke
Current Pharmaceutical Biotechnology Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period
Recent Patents on Anti-Infective Drug Discovery Assessment of Acute Coronary Syndromes: Focus on Novel Biomarkers
Current Medicinal Chemistry MiR-147: Functions and Implications in Inflammation and Diseases
MicroRNA Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis
Current Pharmaceutical Design Mutations of the Apolipoprotein A5 Gene with Inherited Hypertriglyceridaemia: Review of the Current Literature
Current Medicinal Chemistry Case Report on Pulmonary Involvement in a Patient with Adult Still’s Disease
Current Rheumatology Reviews The Role of Thyroid Diseases and their Medications in Cardiovascular Disorders: A Review of the Literature
Current Cardiology Reviews NO Chimeras as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research The Challenges of RSV Vaccines. Where do we Stand?
Recent Patents on Anti-Infective Drug Discovery The Antidiabetic Effects of The Bioactive Flavonoid (Kaempferol-3-O-β-D-6{P- Coumaroyl} Glucopyranoside) Isolated From Allium cepa
Recent Patents on Anti-Infective Drug Discovery Integrins in Pulmonary Inflammatory Diseases
Current Pharmaceutical Design Subject Index To Volume 7
Current Drug Targets Blood Serum Atherogenicity: Cellular Test for the Development of Anti- Atherosclerotic Therapy
Current Pharmaceutical Design Pulmonary Rehabilitation Effects on Heart Rate Recovery in Restrictive Lung Disease Patients
Current Respiratory Medicine Reviews Aliskiren in Patients with Diabetes: A Systematic Review
Current Vascular Pharmacology Prayer at Midlife is Associated with Reduced Risk of Cognitive Decline in Arabic Women
Current Alzheimer Research Cancer Chemoprevention by Targeting the Epigenome
Current Drug Targets